Sinopharm Group Co Ltd
XBER:X2S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
XBER:X2S
|
CN |
|
V
|
Vicat SA
XBER:4HM
|
FR |
|
D
|
Derichebourg SA
XMUN:PNU
|
FR |
|
C
|
Cardiff Oncology Inc
F:XE7C
|
US |
|
A
|
Axon Enterprise Inc
SWB:TCS
|
US |
Wall St Price Targets
X2S Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S is 2.856 EUR with a low forecast of 2.301 EUR and a high forecast of 3.487 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S's stock price target?
Price Target
2.856
EUR
According to Wall Street analysts, the average 1-year price target for X2S is 2.856 EUR with a low forecast of 2.301 EUR and a high forecast of 3.487 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 6%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.
